These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26239729)

  • 41. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
    Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis.
    Kirbs C; Kluwe F; Drescher F; Lackner E; Matzneller P; Weiss J; Zeitlinger M; Kloft C
    Eur J Pharm Sci; 2019 Apr; 131():218-229. PubMed ID: 30731238
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association of
    Zhao T; Shen H; Zhang HL; Feng J; Liu SM; Wang TT; Li HJ; Yu LH
    Pharmacogenomics; 2023 Feb; 24(3):141-151. PubMed ID: 36718992
    [No Abstract]   [Full Text] [Related]  

  • 44. Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.
    Kadam RS; Van Den Anker JN
    Clin Pharmacokinet; 2016 Sep; 55(9):1031-43. PubMed ID: 26979736
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections.
    Wang T; Zhu H; Sun J; Cheng X; Xie J; Dong H; Chen L; Wang X; Xing J; Dong Y
    Int J Antimicrob Agents; 2014 Nov; 44(5):436-42. PubMed ID: 25239277
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
    Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
    Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive Value of FMO3 Variants on Plasma Disposition and Adverse Reactions of Oral Voriconazole in Febrile Neutropenia.
    Wang X; Zhao J; Wen T; Liao X; Luo B
    Pharmacology; 2021; 106(3-4):202-210. PubMed ID: 32998136
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma.
    Williams K; Arron ST
    JAMA Dermatol; 2016 Jun; 152(6):719-20. PubMed ID: 26982740
    [No Abstract]   [Full Text] [Related]  

  • 49. Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring.
    Cojutti PG; Merelli M; Allegri L; Damante G; Bassetti M; Pea F
    Br J Clin Pharmacol; 2019 Jan; 85(1):266-269. PubMed ID: 30414213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
    Moriyama B; Obeng AO; Barbarino J; Penzak SR; Henning SA; Scott SA; Agúndez J; Wingard JR; McLeod HL; Klein TE; Cross SJ; Caudle KE; Walsh TJ
    Clin Pharmacol Ther; 2017 Jul; 102(1):45-51. PubMed ID: 27981572
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.
    Hicks JK; Crews KR; Flynn P; Haidar CE; Daniels CC; Yang W; Panetta JC; Pei D; Scott JR; Molinelli AR; Broeckel U; Bhojwani D; Evans WE; Relling MV
    Pharmacogenomics; 2014 Jun; 15(8):1065-78. PubMed ID: 25084200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of
    Song Y; Jia MX; Yang G; Feng XY; Yin DH; Kang JB; Zhao Q; Duan JJ
    Per Med; 2020 Jan; 17(1):15-22. PubMed ID: 31797717
    [No Abstract]   [Full Text] [Related]  

  • 53. A pharmacokinetic/pharmacodynamic analysis of a standard voriconazole regimen in different CYP2C19 genotypes by Monte Carlo simulation.
    Liao S; Ge T; Zhu L; Zhao Y; Yang J; Xu G
    Pharmazie; 2015 May; 70(5):306-9. PubMed ID: 26062298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient.
    Ambrosioni J; Coll S; Manzardo C; Nicolás D; Agüero F; Blanco JL; Tuset M; Brunet M; Gatell JM; Miró JM
    J Antimicrob Chemother; 2016 Apr; 71(4):1125-7. PubMed ID: 26755498
    [No Abstract]   [Full Text] [Related]  

  • 55. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians.
    Chawla PK; Nanday SR; Dherai AJ; Soman R; Lokhande RV; Naik PR; Ashavaid TF
    Int J Clin Pharm; 2015 Oct; 37(5):925-30. PubMed ID: 26024717
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Why are the Therapeutic Drug Monitoring Results of Voriconazole Inconsistent with CYP2C19 Genetic Testing?
    Kong L; Xie M; Jiang M; Zhu Y
    J Coll Physicians Surg Pak; 2023 May; 33(5):598-599. PubMed ID: 37190702
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients.
    Zhao YC; Lin XB; Zhang BK; Xiao YW; Xu P; Wang F; Xiang DX; Xie XB; Peng FH; Yan M
    Clin Transl Sci; 2021 Mar; 14(2):702-711. PubMed ID: 33202102
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report.
    Beata S; Donata UK; Jarosław D; Tomasz W; Anna WH
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1103-1106. PubMed ID: 28247033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients.
    Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH
    Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Voriconazole hepatotoxicity as a result of steroid withdrawal in a patient with allergic bronchopulmonary aspergillosis.
    Blanco-Dorado S; Marques Afonso AT; Bandín-Vilar EJ; Novo-Veleiro I; Ferrón Vidán F; Latorre-Pellicer A; Maroñas Amigo O; Fernández-Ferreiro A; Lamas MJ
    Br J Clin Pharmacol; 2019 Feb; 85(2):460-462. PubMed ID: 30537018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.